IBRX Q2 2024 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+2453.7% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$99M-9487.4% margin

Net Income

-$135M-12852.3% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+2517.5%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$101M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$444M

Total Liabilities

$1.1B

Stockholders' Equity

-$698M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$41,000	+2453.7%
Gross Profit	$1M	$41,000	+2453.7%
Operating Income	-$99M	-$85M	-16.7%
Net Income	-$135M	-$138M	+2.4%

Revenue Segments

Product

$990,00095%

Product and Service, Other

$57,0005%